Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Kymera Therapeutics, Inc. by 25.8%, owning approximately 85,046 shares worth $2.33 million after selling 29,541 shares in the first quarter.
• Despite some reductions in holdings, other investors such as the Teacher Retirement System of Texas and Vanguard Group Inc. increased their positions in Kymera Therapeutics, indicating continued interest in the company.
• Kymera Therapeutics reported $22.10 million in revenue for the most recent quarter, significantly exceeding analysts' estimates, while posting an earnings per share of ($0.82) that beat expectations by $0.10.

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 25.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,046 shares of the company's stock after selling 29,541 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Kymera Therapeutics worth $2,328,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV raised its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after buying an additional 406 shares during the last quarter. State of Wyoming bought a new position in Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. bought a new position in Kymera Therapeutics during the fourth quarter worth $55,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Kymera Therapeutics by 7.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after purchasing an additional 2,011 shares during the period.

Kymera Therapeutics Stock Down 1.8%

KYMR traded down $0.79 during trading hours on Friday, hitting $42.96. The stock had a trading volume of 393,426 shares, compared to its average volume of 748,287. The company's fifty day simple moving average is $43.58 and its 200 day simple moving average is $36.55. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $53.27. The stock has a market cap of $2.80 billion, a PE ratio of -13.86 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. During the same quarter last year, the firm posted ($0.69) EPS. The firm's revenue for the quarter was up 114.6% on a year-over-year basis. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price for the company in a research report on Monday, June 2nd. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Jefferies Financial Group set a $64.00 target price on shares of Kymera Therapeutics and gave the company a "buy" rating in a research report on Wednesday, June 25th. BTIG Research reiterated a "buy" rating and set a $59.00 target price on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Finally, B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target for the company in a research report on Wednesday. Two research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $59.11.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il bought 317,167 shares of Kymera Therapeutics stock in a transaction on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the acquisition, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. This represents a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is owned by corporate insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.